The Global Blindness Crisis: Top 5 Preventable Causes of Vision Loss and Why Early Eye Care Matters

Research-informed explainer — last updated April 12, 2026

More than 1.1 billion people worldwide live with vision impairment or blindness, and at least 90% of those cases are either preventable or treatable with interventions that already exist — the gap between what is possible and what is happening is one of the most consequential unmet needs in global health. The five leading causes of preventable vision loss — cataracts, uncorrected refractive error, glaucoma, age-related macular degeneration, and diabetic retinopathy — share a common feature: early detection and intervention preserves vision that once lost cannot be recovered.

This article draws on research from five specialist physicians whose work defines how the global burden of vision loss is measured and what can be done about it. David Friedman, M.D., Director of the Glaucoma Service at Massachusetts Eye and Ear, is a principal contributor to the GBD 2020 global causes of blindness study (3,335 citations), the 2020 vision impairment burden analysis (2,889 citations), global blindness prevalence trends (2,187 citations), and the Lancet Global Health Commission on Global Eye Health (1,423 citations) — the most comprehensive epidemiology dataset on blindness in existence. Tien Wong, M.D., at Houston Methodist Hospital, published the foundational disease-specific burden papers for glaucoma (6,737 citations), myopia (5,168 citations), AMD (5,098 citations), and diabetic retinopathy (4,798 citations). Jeffrey Heier, MD, at Ophthalmic Consultants of Boston, published pivotal AMD treatment trials demonstrating that early intervention with ranibizumab prevents vision loss (5,820 citations), providing the treatment-efficacy data underpinning why early AMD care matters. Felipe Medeiros, M.D., Vice Chair of Research at Bascom Palmer Eye Institute, published the most-cited glaucoma pathophysiology and treatment review in JAMA (3,932 citations). Ivana Kim, M.D., Associate Professor of Ophthalmology at Harvard Medical School and Co-Director of the AMD Center of Excellence at Mass Eye and Ear, led a large genome-wide association study identifying 52 AMD genetic loci (1,590 citations), advancing the understanding of who is at greatest genetic risk.

The scale of the problem

Dr. Friedman's GBD 2020 analysis found that as of 2020, 43.3 million people were blind and 295 million had moderate-to-severe distance vision impairment. An additional 510 million people had near vision impairment from uncorrected presbyopia. Total affected: over 1.1 billion people.

The Lancet Global Health Commission led by Dr. Friedman's group projected that without increased action, the number of people with vision impairment will triple by 2050 as populations age and diabetes rates rise. The economic cost of unaddressed vision impairment — lost productivity, dependence, and reduced quality of life — amounts to $411 billion annually.

What makes this extraordinary is that the Commission estimated approximately 90% of this burden is preventable or treatable. The problem is not a lack of solutions; it is a lack of access, awareness, and systematic screening.

Cause 1: Cataracts

Cataracts — the clouding of the eye's natural lens — remain the leading cause of blindness globally, responsible for 33% of all blindness according to the GBD 2020 data. They are 100% treatable with a 15-minute outpatient surgery that restores vision immediately and costs as little as $25 in high-volume programs. Yet in low- and middle-income countries, cataract surgery rates are 10 to 50 times lower than what is needed.

In high-income countries, cataracts are typically addressed before they cause significant functional disability, making them a smaller contributor to blindness here. But delays in surgical care — due to cost, access, or fear — still account for unnecessary vision loss among older adults in underserved communities even in the United States.

Cause 2: Uncorrected refractive error

Refractive errors — myopia (nearsightedness), hyperopia (farsightedness), and astigmatism — are the most common cause of distance vision impairment worldwide and the second leading cause of blindness. Correcting them requires only glasses, contact lenses, or laser surgery. Yet an estimated 826 million people who need glasses do not have them.

Dr. Wong's myopia burden study projected that by 2050, 4.8 billion people — half the world's population — will have myopia, and nearly 1 billion will have high myopia (above -6 diopters). High myopia is not just a refractive nuisance: it dramatically increases the risk of retinal detachment, myopic macular degeneration, glaucoma, and cataract. The myopia epidemic, driven by reduced outdoor time and increased screen use in children, is creating a population-level blindness risk for the second half of this century.

Cause 3: Glaucoma

Glaucoma is the leading cause of irreversible blindness worldwide, affecting an estimated 76 million people in 2020 and projected to affect 111.8 million by 2040 according to Dr. Wong's prevalence analysis. Unlike cataracts, the vision lost to glaucoma cannot be recovered — which is why the irreversible qualifier matters.

The central challenge is the symptom profile: primary open-angle glaucoma causes no pain, no visual symptoms, and no warning signs until 30–40% of optic nerve fibers are already dead. In the United States, half of all glaucoma patients do not know they have the disease. In low-income settings, the undetected fraction is far higher.

Dr. Medeiros's JAMA review establishes that intraocular pressure-lowering treatment — with drops, laser, or surgery — prevents further nerve fiber loss in the vast majority of patients. The tragedy of glaucoma blindness is that it is almost entirely avoidable with regular screening in at-risk populations.

Cause 4: Age-related macular degeneration

Age-related macular degeneration (AMD) is the leading cause of irreversible legal blindness in adults over 50 in high-income countries. Dr. Wong's global AMD meta-analysis found approximately 196 million people affected in 2020, projected to reach 288 million by 2040 as populations age.

AMD has two forms: dry (geographic atrophy) and wet (choroidal neovascularization). Dry AMD progresses slowly over years; there is no approved therapy that reliably halts it, though complement inhibitors were recently approved for geographic atrophy. Wet AMD progresses rapidly — patients can lose 15 letters of vision in weeks if untreated — but responds dramatically to anti-VEGF injections.

Dr. Heier's MARINA trial established that monthly ranibizumab prevented vision loss in 94.5% of patients with wet AMD over two years. The ANCHOR trial showed that ranibizumab patients gained an average of +11 letters at one year compared with +2 letters with photodynamic therapy. These outcomes — verified across dozens of subsequent trials — make wet AMD one of the great treatment successes of modern ophthalmology, provided patients receive injections promptly and consistently.

Dr. Kim's GWAS identified 52 genetic loci associated with AMD risk, with complement factor H and ARMS2/HTRA1 conferring the strongest risk. First-degree relatives of AMD patients have two to four times higher lifetime risk, supporting targeted screening in this population.

Cause 5: Diabetic retinopathy

Diabetic retinopathy affects approximately 93 million people worldwide and is the leading cause of new blindness in working-age adults in high-income countries according to Dr. Wong's global prevalence data. With the global diabetes epidemic projected to reach 643 million people by 2030, DR burden will escalate substantially.

Unlike wet AMD or glaucoma — which affect patients regardless of lifestyle — diabetic retinopathy is directly caused by a modifiable condition. Every percentage point reduction in HbA1c reduces the risk of retinopathy progression by approximately 37%. Blood pressure control provides additional protection. And annual dilated eye exams allow detection and treatment at stages when intervention reliably prevents blindness.

The challenge is systemic: in many countries, annual eye exams for diabetic patients do not happen. In the United States, only about 50–60% of diabetic patients receive the recommended annual dilated exam, leaving millions at undetected risk.

Why early eye care is the non-negotiable intervention

The unifying thread across all five conditions is that outcomes are dramatically better — and costs dramatically lower — when disease is caught early:

• Cataracts: Treatment before vision drops below 20/40 in both eyes preserves driving ability and falls prevention
• Refractive error: Correcting myopia in children during school years prevents amblyopia and avoids high myopia complications in adulthood
• Glaucoma: Treatment started before 30% nerve fiber loss maintains functional vision for life; treatment started at 70% loss cannot recover what is gone
• AMD: Anti-VEGF therapy for wet AMD preserves or restores vision only in eyes that still have living photoreceptors — waiting until vision is severely reduced means starting too late
• Diabetic retinopathy: Proliferative DR and DME detected before extensive neovascularization respond to laser or injections; tractional retinal detachment requires surgery with far worse prognosis

Questions to ask your doctor

• When did I last have a comprehensive dilated eye exam, and is that often enough given my age and risk factors?
• Do I have any early signs of AMD, glaucoma, or retinopathy that require monitoring or treatment?
• If I have diabetes, is my eye exam happening every year, and does my endocrinologist coordinate with my ophthalmologist?
• Does my family history of AMD, glaucoma, or high myopia put me at higher inherited risk?
• Are there modifiable risk factors — blood pressure, blood sugar, smoking, UV exposure — I should be addressing to protect my eyes?
• What screening interval is appropriate for someone with my age, health history, and family history?

The bottom line

The global vision loss crisis is, at its core, a crisis of prevention and access rather than a lack of treatments. Cataracts can be cured with a 15-minute surgery; glaucoma can be stabilized with drops or laser; wet AMD responds remarkably to monthly injections; diabetic retinopathy can be prevented through glycemic control and detected with an annual eye exam. The evidence base is robust, the interventions exist, and the only gap that remains is ensuring that people know to seek care before permanent damage is done. For the 1.1 billion people living with avoidable vision impairment, the most powerful tool available remains the same as it has always been: a comprehensive eye exam.